- noodls•4 months ago
pSivida Corp. Reports Fiscal 2017 First Quarter Results and Provides Update on Corporate Objectives & Milestone Timeline
November 7, 2016 New Leadership Focused on Increasing Commercial Potential of Proven Durasert™ Sustained Release Platform Company Continues Focus on MAA and NDA Filings for Uveitis Product in 2017 Conference ...
- noodls•5 months ago
pSivida Corp. Announces First Quarter Fiscal Year 2017 Financial Results Release Date and Conference Call Information
October 31, 2016 WATERTOWN, Mass., Oct. 31, 2016 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products primarily for treating ...
- noodls•6 months ago
October 4, 2016 Study is the Second of Two Ongoing Phase 3 Trials in Support Of Product Registration in the US EU Filing Remains on Track for 1Q2017 Filing WATERTOWN, Mass., Oct. 04, 2016 (GLOBE NEWSWIRE) ...
PVA.AX: Summary for PSIVIDACOR CDI - Yahoo Finance
pSivida Corp. (PVA.AX)
ASX - ASX Delayed price. Currency in AUD
Add to watchlist
|Day's range||2.22 - 2.25|
|52-week range||2.10 - 5.25|
|PE ratio (TTM)||-4.10|
|Dividend & yield||N/A (N/A)|
|1y target est||N/A|